FDA Warns Telehealth Seller NativeMed Over Misleading Compounded Semaglutide and Tirzepatide Claims
On June 8, 2026, FDA issued a warning letter to NativeMed after a March 2026 review of nativemed.net, which offers compounded semaglutide and tirzepatide products. FDA says compounded tirzepatide products pictured on the site feature NativeMed’s logo on the label, "suggesting NativeMed is the compounder of those drugs when in fact it is not," and that claims such as "The same active ingredient in Ozempic® and Wegovy®" represent the products as FDA-approved when "Compounded drug products are not FDA-approved." FDA requested a written response within 15 business days.
What this meansA brand name on the vial does not mean that company made the drug — asking who actually compounds and ships a GLP-1 prescription is a basic vetting step for any telehealth service.
Source: FDA original ↗